Kynurenine pathway metabolites and suicidality  by Bryleva, Elena Y. & Brundin, Lena
lable at ScienceDirect
Neuropharmacology 112 (2017) 324e330Contents lists avaiNeuropharmacology
journal homepage: www.elsevier .com/locate/neuropharmInvited reviewKynurenine pathway metabolites and suicidality
Elena Y. Bryleva, Lena Brundin*
Laboratory of Behavioral Medicine, Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USAa r t i c l e i n f o
Article history:
Received 11 November 2015
Received in revised form
19 January 2016
Accepted 22 January 2016







Depression* Corresponding author. Laboratory of Behavioral
degenerative Science, Van Andel Research Institute
Rapids, MI 49503, USA.
E-mail address: Lena.Brundin@vai.org (L. Brundin)
http://dx.doi.org/10.1016/j.neuropharm.2016.01.034
0028-3908/© 2016 The Authors. Published by Elseviera b s t r a c t
Suicide is a major global problem, claiming more than 800,000 lives annually. The neurobiological
changes that underlie suicidal ideation and behavior are not fully understood. Suicidal patients have
been shown to display elevated levels of inﬂammation both in the central nervous system and the pe-
ripheral blood. A growing body of evidence suggests that inﬂammation is associated with a dysregulation
of the kynurenine pathway in suicidal patients, resulting in an imbalance of neuroactive metabolites.
Speciﬁcally, an increase in the levels of the NMDA receptor agonist quinolinic acid and a simultaneous
decrease in neuroprotective metabolites have been observed in suicidal patients, and may contribute to
the development of suicidality via changes in glutamate neurotransmission and neuroinﬂammation. The
cause of the dysregulation of kynurenine metabolites in suicidality is not known, but is likely due to
differential activity of the involved enzymes in patients. As knowledge in these areas is rapidly growing,
targeting the kynurenine pathway enzymes may provide novel therapeutic approaches for managing
suicidal behavior.
This article is part of the Special Issue entitled ‘The Kynurenine Pathway in Health and Disease’.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Suicide is the 14th cause of years of life lost (Mortality and
Causes of Death, 2015) with over 800,000 deaths reported glob-
ally every year (World Health Organization, 2014). This high deathMedicine, Center for Neuro-
, 333 Bostwick Ave., Grand
.
Ltd. This is an open access article utoll is still likely to be under-reported, due to the fact that suicide is
stigmatized and illegal in some countries (Varnik, 2012). It is esti-
mated that suicide attempts are 10e20 times more frequent than
the number of completed suicides. Both suicide attempts and
deaths by suicide result in a great psychological and economic
burden for individuals, families and countries. The World Health
Organization has recently declared suicide a major public health
problem worldwide (World Health Organization, 2014). In the US
alone, the economic cost of death by suicide is estimated to bemore
than $44 billion annually (Centers for Disease Control andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Despite an increase in available clinical treatment options for
suicidality, including pharmacological agents as well as electro-
convulsive treatment, the incidence rate of suicide is increasing in
many countries (World Health Organization, 2014). Even though
almost half of the suicidal patients make contact with mental
health and primary care providers within one month of their sui-
cide, the health care system fails to accurately detect the risk and
prevent suicide (Da Cruz et al., 2011). A difﬁculty in this area is to
correctly identify patients with a clear suicidal intent among pa-
tients exhibiting suicidal ideation; not the least because patients
with a deﬁnite intent may ultimately hide this from family and
health care providers. Consequently, there is a critical need to
improve suicide risk detection by means of identifying biological
risk markers, as well as to develop effective, novel pharmacological
interventions.
Suicidal behavior is not conﬁned to a particular diagnostic group
of patients, and as such is a transnosological phenomenon
(Leenaars, 1992). The majority of patients who complete suicide
have an underlying psychiatric disorder, which can range from
psychotic disorders, such as schizophrenia, to mood disorders,
including depression and bipolar disorder, as well as anxiety and
posttraumatic stress disorders. Importantly, it is plausible that the
underlying pathological molecular mechanisms, associated with
suicidal ideation and behavior, are shared across these diagnostic
boundaries. The current treatment options for suicidality tend to
depend on the psychiatric diagnosis and often consist of antide-
pressants and anxiolytics (Wasserman et al., 2012). However, the
ﬁrst-line of choice antidepressant treatments, including SSRIs, and
SNRIs, have drawbacks since it can take weeks to develop beneﬁcial
mood-enhancing effects, and the risk for suicidality has been re-
ported to increase during the ﬁrst weeks of treatment, especially in
children and adolescents (Wasserman et al., 2012). Pharmacolog-
ical treatment with lithium in mood disorders (Baldessarini et al.,
2006; Guzzetta et al., 2007), clozapine in schizophrenia (Meltzer
and Baldessarini, 2003), and electroconvulsive therapy in
treatment-resistant depression (Kennedy et al., 2009) have proven
effective in decreasing suicidal behavior. In addition, a robust and
rapid (within hours) antidepressant and anti-suicidal effect is
produced by intravenous injection of ketamine, which is an NMDA-
receptor antagonist (Fond et al., 2014; Zarate et al., 2013). The
biological mechanisms behind the beneﬁcial effects of these
treatments on suicidal behavior are not completely understood.
2. Risk factors of suicide
Suicidal behavior is thought to be triggered by an intricate
interplay between genetic predispositions and environmental fac-
tors (Roy et al., 2009). The genetic component of suicidal behavior,
including attempts and suicide completion, is estimated to be
around 40% (McGufﬁn et al., 2010). Recently, epigenetic changes,
including hypermethylation of the brain-derived neurotrophic
factor (BDNF) promoter (Kang et al., 2013; Kim et al., 2014), have
been proposed to be important in depression and suicidality and
may provide the platform for some of the gene-environment in-
teractions (Lockwood et al., 2015). The single most important pre-
dictor of death by suicide is previous self-harm (Hawton and van
Heeringen, 2009). Psychiatric disorders, especially Major Depres-
sive Disorder (MDD) and bipolar disorder, are present in 90% of
individuals who complete suicides (Harris and Barraclough, 1997).
Certain personality traits have been proposed to act as additional
risk factors in individuals with and without psychiatric disease.
These include higher levels of impulsivity and aggression, espe-
cially in younger suicide victims (Dumais et al., 2005; Perroud et al.,
2011) and hopelessness (David Klonsky et al., 2012). Theneurobiological changes implicated in suicidal behavior are
not fully understood. Dysregulation of the hypothal-
amicepituitaryeadrenal (HPA) axis (Mann, 2003) and serotonergic
neurotransmission (Bach and Arango, 2012) are frequently detected
in individuals exhibiting suicidal behavior. Inﬂammation is thought
to be a contributing factor as inﬂammatory mediators, such as cy-
tokines, closely and reciprocally interact with both the HPA axis and
serotonin system. Inﬂammation also causes activation of the
kynurenine pathway of tryptophan (TRP) degradation. As is the
topic of this review, accumulating evidence suggest that a dysre-
gulation of the enzymes in the kynurenine pathwaymay contribute
to the neurobiological changes observed in suicidal patients.3. Kynurenine pathway and inﬂammation
The kynurenine pathway is initiated by the conversion of TRP to
N-formylkynurenine by any of these enzymes: indoleamine 2,3-
dioxygenase 1 (IDO1), IDO2, or tryptophan 2,3-dioxygenase (TDO)
(Fig. 1). The resulting N-formylkynurenine is further degraded to
kynurenine (KYN), which is a precursor of bioactive compounds,
including quinolinic acid (QUIN), kynurenic acid (KYNA), picolinic
acid (PIC), and 3-hydroxyanthranilic acid (3-HAA) (Schwarcz et al.,
2012). The kynurenine pathway is responsible for over 90% of TRP
degradation in the periphery (Leklem, 1971) and many organs and
cell types, including liver, intestine, brain and immune cells, ex-
press several of the enzymes in this pathway. Pro-inﬂammatory
cytokines, including interferon-g (IFN-g), interleukin-1b (IL-1b)
and IL-6, can further induce IDO-1 and TDO, and thus activate this
pathway (Schwieler et al., 2015; Urata et al., 2014). Since TRP is also
a precursor for neurotransmitter serotonin, it has been hypothe-
sized that induction of the kynurenine pathway by inﬂammation
may reduce the availability of TRP and consequently lead to
reduced serotonin synthesis (Maes et al., 2011). This could theo-
retically contribute to the decreased levels of 5-
hydroyxyindoleacetic acid, a main metabolite of serotonin, that
has been observed in the cerebrospinal ﬂuid (CSF) of suicide
attempters (Asberg et al., 1976). However, currently there is no clear
evidence demonstrating that inﬂammation causes a decrease in
brain serotonin levels through induction of the kynurenine
pathway in depressed and suicidal patients.4. Kynurenine pathway metabolites in psychiatric disorders
and suicidal behavior
In 2011, the ﬁrst report was published on the relationship be-
tween dysregulation of the kynurenine pathway and suicidal
behavior (Sublette et al., 2011). In that study, Sublette et al. detected
elevated plasma KYN levels in suicide attempters with depression,
compared to patients with depression but no history of suicidality.
A more recent study by Bradley et al. found a 40% decrease in
plasma TRP levels and a 40% increase in KYN/TRP ratio in suicidal
adolescents with MDD, compared to non-suicidal individuals with
MDD and healthy controls (Bradley et al., 2015). KYN, like TRP, is
able to pass through the blood brain barrier (BBB) into the brain
(Schwarcz et al., 2012). In the brain, KYN can be differentially
processed by either astrocytes or microglia to produce distinct
neuroactive compounds. While the synthesis of 3-
hydroxykynurenine (3-HK) and its downstream metabolites,
including 3-HAA and QUIN, takes place in microglia and other cells
of monocytic origin (Guillemin et al., 2003), the synthesis of KYNA
occurs in astrocytes, neurons and oligodendrocytes (Du et al., 1992;
Guillemin et al., 2001; Wejksza et al., 2005).
Fig. 1. A diagram of the kynurenine pathway. Enzymes are in italics and metabolites are boxed. The metabolites discussed in detail are in bold. Abbreviations: IDO, indoleamine-2,3-
dioxygenase; TDO, tryptophan-2,3-dioxygenase; KATs, kynurenine aminotransferases; KMO, kynurenine-3-monooxygenase; 3-HAO, 3-hydroxyanthranilate-3,4-dioxygenase;
ACMSD, aminocarboxymuconate-semialdehyde decarboxylase; QPRT, quinolinate phosphoribosyltransferase; NAD, nicotinamide adenine dinucleotide.
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QUIN is considered to be an important kynurenine pathway
metabolite in terms of its biological activity. It is non-enzymatically
produced by spontaneous conversion from the precursor 2-amino-
3-carboxymuconic-6-semialdehyde (ACMS) in the absence of the
competing enzyme 2-amino-3-carboxymuconic-6-semialdehyde
decarboxylase (ACMSD) (Fig. 1). ACMSD can convert ACMS to
picolinic acid, but when the enzyme is saturated, inactive, or not
present, QUIN is instead spontaneously formed. Whereas the
detailed regulation of this enzyme is yet to be established, it is
known that environmental contaminants (e.g. phthalate esters)
and the antituberculosis drug pyrazinamide are capable of inhib-
iting ACMSD activity, thus increasing the amount of QUIN
(Fukuwatari et al., 2004, 2002). Changes in the nutritional status
and the presence of some diseases states, such as diabetes and renal
failure, can lead to alteration of ACMSD expression and activity
(Egashira et al., 2007; Fukuoka et al., 2003). Saturation of ACMSD
occurs when the level of upstream precursor ACMS is elevated,
such as under the conditions of increased inﬂammation, leading to
increased QUIN production. The half-life of QUIN is approximately
20 min as it gets rapidly broken down by the next enzyme in the
kynurenine pathway, quinolinate phosphoribosyl transferase
(QPRT), which is found both in the CNS and peripheral organs
(Schwarcz et al., 2012). Therefore, the levels and degree of activity
of QPRT also regulate QUIN concentration in the tissue of interest
(Fig. 1).
In the brain, QUIN is primarily produced by microglial cells and
inﬁltrating macrophages. It is considered to be neurotoxic through
several mechanisms (Espey et al., 1997; Guillemin et al., 2001;Heyes et al., 1996). One of the mechanisms includes activation of
the glutamate N-methyl-D-aspartic acid receptors (NMDARs). QUIN
speciﬁcally binds to NMDARs containing the NR1 þ NR2A and the
NR1 þ NR2B subunits, which are primarily expressed in the fore-
brain (de Carvalho et al., 1996). Consequently, the neurons within
hippocampus, striatum and neocortex are most vulnerable to QUIN
toxicity, while spinal cord and cerebellar neurons are less sensitive
(Guillemin, 2012a). A recent study reported that the expression of
these NMDAR subunits in dorsolateral prefrontal cortices was
higher in suicide victims than controls and most pronounced in
females (Gray et al., 2015). Potentially, individuals with a higher
expression of these NMDARs would be more vulnerable to
increased levels of QUIN e the receptors' agonist. A second mech-
anism of QUIN neurotoxicity can occur through an increase in
glutamate release by neurons and inhibition of its uptake and
degradation by astrocytes (Guillemin, 2012b). This leads to elevated
extracellular glutamate levels and to overstimulation of the gluta-
matergic system. In addition, QUIN is capable of forming complexes
with iron which leads to formation of reactive oxygen species and
can cause lipid peroxidation (Goda et al., 1996; Stipek et al., 1997).
We have found that the QUIN levels in CSF of suicide attempters
are around 300% of the levels in healthy controls (Erhardt et al.,
2013). In addition, CSF QUIN correlates with CSF IL-6, suggesting
that the generation of QUIN is induced by an inﬂammatory process.
We have also found a positive correlation between CSF QUIN and
suicidal intent. Although the highest CSF QUIN levels were at the
time of a suicide attempt, levels remain signiﬁcantly elevated by
around 150% over a period of 2 years (Bay-Richter et al., 2015).
Theoretically, the elevated levels of QUIN and its neurotoxic effects
could contribute to the structural deﬁcits and functional changes
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atric patients with suicidal behavior (van Heeringen et al., 2014). In
agreement with this hypothesis, Steiner et al. reported an increase
in density of QUIN-reactive microglia cells in some regions of
anterior cingulate cortex (i.e. subgenual anterior cingulate cortex
(sACC) and anterior midcingulate cortex (aMCC)) in postmortem
brains of depressed patients who died by suicide (Steiner et al.,
2011). However, in a recent follow-up study by Steiner's team a
decrease in QUIN-immunoreactive microglia was observed in the
hippocampal regions of the same suicide victims, suggesting some
brain-region differences in the distribution of QUIN-positive
microglial cells (Busse et al., 2015).
Our initial interest in studying QUIN in suicidal patients was
motivated by several small studies which showed that ketamine, an
anesthetic agent that pharmacologically is an NMDAR antagonist, is
capable of rapidly inducing anti-suicidal effects (DiazGranados
et al., 2010; Larkin and Beautrais, 2011; Price et al., 2009; Zarate
et al., 2012). The effect of ketamine on suicidal ideation has
proven to occur as early as 40 min after the start of infusion and to
be long lasting, up to 10 days after infusion (DiazGranados et al.,
2010; Ibrahim et al., 2012; Larkin and Beautrais, 2011; Zarate
et al., 2012). Later clinical studies assessing the effect of ketamine
on depression and suicidal behavior have conﬁrmed the beneﬁcial
effects (Price and Mathew, 2015). In addition, a study in an exper-
imental model of depression demonstrated that ketamine could
abrogate the development of bacterial lipopolysaccharide (LPS)-
induced depressive-like behavior in mice (Walker et al., 2013). Mice
intraperitoneally injected with LPS display inﬂammatory induction
of IDO in the brain and develop depressive-like symptoms, which
are mediated by NMDAR activation, likely caused by the increased
production of QUIN (O'Connor et al., 2009; Walker et al., 2013).
Therefore, hyperstimulation of NMDAR may contribute to the
pathophysiology of depression and suicidal behavior, although it
should be noted that ketamine has additional effects in the brain
(Abdallah et al., 2015).
4.2. Kynurenic acid
KYNA is produced from KYN by kynurenine aminotransferase
enzymes and, within the central nervous system (CNS), is synthe-
sized in astrocytes, neurons, and oligodendrocytes (Fig. 1) (Du et al.,
1992; Guillemin et al., 2001; Wejksza et al., 2005). KYNA is a
glutamate receptor antagonist capable of inhibiting a range of
ionotropic excitatory amino acid receptors, including NMDARs,
AMPA receptors (AMPARs) and kainite receptors. In addition, KYNA
inhibits a7 nicotinic acetylcholine receptor (a7nAChR) and in-
teracts with the aryl hydrocarbon receptor and an orphan G
protein-coupled receptor GPR35 (Stone et al., 2013). It is through
activation of GPR35 that KYNA is thought to reduce extracellular
brain glutamate levels and prevent the release of pro-inﬂammatory
cytokines in cell lines (Moroni et al., 2012). In addition to its role in
receptor binding, KYNA is also an antioxidant capable of scavenging
free radicals (Hardeland et al., 1999; Lugo-Huitron et al., 2011).
KYNAs physiological role is neuroprotective and anticonvulsive,
however, elevated levels of KYNA correlate with cognitive deﬁcits
and psychosis (Erhardt et al., 2009). Patients with schizophrenia
spectrum disorder display an approximate 50e70% increase in the
CSF KYNA levels compared to healthy controls (Erhardt et al., 2003;
Linderholm et al., 2012). Interestingly, a study on suicidal patients
with schizophrenia showed that they have signiﬁcantly lower
levels of KYNA compared to non-suicidal patients (Carlborg et al.,
2013). We observed that the CSF KYNA levels were decreased by
approximately 35% over two years following a suicide attempt, and
low levels correlated with more severe depressive and suicidal
symptoms (Bay-Richter et al., 2015). As KYNA and QUIN haveopposing effects on the NMDAR, the QUIN/KYNA ratio might be a
relevant measure suggestive of the overall level of NMDAR stimu-
lation. The ratio is sometimes referred to as a neurotoxic ratio in the
literature, although the effects of the metabolites on the receptor
are primarily agonistic/antagonistic prior to any neurotoxic effects.
The CSF QUIN/KYNA ratio was more than 2-fold elevated in suicide
attempters compared to healthy subjects, which suggests an in-
crease in net positive effect on NMDAR agonism in suicidality
(Erhardt et al., 2013).
Although several studies, mentioned above, point to suicidal
patients as highly relevant in terms of exhibiting pronounced bio-
logical changes, such as an exacerbated imbalance of the kynur-
enine pathway metabolites, scientiﬁc studies on this group of
patients are relatively sparse. Clinical studies on patients with
depression frequently exclude patients with suicidal ideation or
behavior, and others include suicidal patients amongst non-suicidal
depressive patients without accounting for the presence of suici-
dality. In agreement with our ﬁndings, a previous study on pe-
ripheral blood from depressed patients, of which almost 20% had a
previous suicide attempt, detected a decrease of 32% in the level of
KYNA in the patients (Myint et al., 2007). The study did not attempt
to measure QUIN. A recent study by Savitz et al. found that both
patients with current and remitted MDD (both groups included
suicide attempters) had a decreased putative neuroprotective
KYNA/QUIN ratio compared to the healthy controls, which indi-
cated the presence of a persistent dysregulation of the kynurenine
pathway (Savitz et al., 2015).
4.3. Picolinic acid
As mentioned in the section related to the production of QUIN,
PIC is produced from an unstable precursor metabolite, ACMS, by
an enzymatic reaction carried out by the enzyme ACMSD (Fig. 1). It
has not yet been established whether PIC is able to cross the BBB
and enter CNS from the periphery under physiological conditions,
but PIC is readily detectable in CSF samples from humans (own
unpublished observations) (Coggan et al., 2009; Wang et al., 2013).
ACMSD is expressed in the brain, although the expression rate is
lower than in kidney and liver (Pucci et al., 2007). Interestingly, in
animal models the expression of ACMSD in the brain can be
induced or reduced under certain conditions such as streptozocin-
induced diabetes or low protein diet, respectively (Fukuoka et al.,
2003). Once PIC has been produced, it is not degraded by any
enzyme, but is excreted by urine or bile as an end-product of the
kynurenine pathway. A study by Guillemin et al. found that
neuronal and some glial cells in the cortex and hippocampus ex-
press ACMSD. Primary neuronal cultures isolated from fetal human
brains were also found to constitutively produce PIC (Guillemin
et al., 2007). The most ﬁrmly established physiological character-
istic of PIC is its ability to efﬁciently chelate iron, copper and other
metals (Grant et al., 2009). In addition, PIC is able to antagonize
QUIN neurotoxicity in both cell culture and animal models by a
currently unknown mechanism, which may involve chelation of
endogenous zinc (Beninger et al., 1994; Chen et al., 2011; Cockhill
et al., 1992; Jhamandas et al., 1998).
We have recently detected a signiﬁcant decrease in the CSF PIC
levels of suicide attempters compared to healthy controls (in sub-
mission). The reduced PIC levels are consistent in several cohorts of
suicide attempters and may indicate a decreased function of the
enzyme ACMSD in suicidal individuals, which would contribute to
the increased production of QUIN and neuroinﬂammation observed
in the patients. Several clinical studies have also discovered
promising antidepressant effects of chromium picolinate complex
in atypical depression (Davidson et al., 2003; Docherty et al., 2005)
and potentiation of pharmacotherapy for dysthymic disorder
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animal model of chronic unpredictable mild stress increases the
concentration of cortical and cerebellar serotonin levels and de-
creases plasma corticosterone levels, which could be involved in
some observed improvements in depression and anxiety symptoms
(Dubey et al., 2015). The observed beneﬁcial effects of chromium
picolinate are commonly attributed to the presence of chromium in
the complex, while PIC is generally considered to be the non-active
ingredient used to solubilize bioactive chromium. Nevertheless,
PIC's protective properties against QUIN toxicity in vitro and in
animal models, as well as our ﬁnding of its low levels in suicide
attempters, challenge the notion of PIC as bystander and point to its
potential role in managing the depressive symptoms.
4.4. 3-Hydroxyanthranilic acid
In the periphery, 3-hydroxyanthranilic acid (3-HAA) is produced
from 3-HK. In the brain, however, anthranilic acid is the preferred
precursor for 3-HAA production by kynureninase (Fig.1) (Baran and
Schwarcz, 1990). 3-HAA is a highly reactive compound and can be
either a pro-oxidant (Goldstein et al., 2000) or anti-oxidant
(Christen et al., 1990) depending on the local redox conditions
(Darlington et al., 2010). A recent study by Bradley et al. did not ﬁnd
signiﬁcant differences in the plasma levels of 3-HAA between 20
suicidal depressed adolescents, 30 depressed youth without suici-
dality, and 22 healthy controls (Bradley et al., 2015). No difference
was detected in plasma 3-HAA levels or in kynureninase enzyme
expression between MDD patients and healthy controls (Hughes
et al., 2012). Several studies investigating depression in youth
have discovered that only in adolescents that have MDD with
melancholic features, and not MDD without melancholic features
or healthy controls, there is a positive correlation between plasma
3-HAA/KYN and severity of MDD episode. Moreover, there was also
a positive association between the levels of 3-HAA and striatal total
choline, a cell membrane breakdown biomarker, suggesting the
possibility of the existence of distinct neurobiological characteris-
tics in MDD with melancholic features in adolescence (Gabbay
et al., 2010a, 2010b).
5. Discussion and conclusions
There is accumulating evidence that dysregulation of the
kynurenine pathway, involving changes in the concentration of key
metabolites, occurs in some patients with suicidal behavior. The
observed changes in levels of bioactive kynurenine pathway me-
tabolites such as QUIN, KYNA, PIC, and 3-HAA could be important in
psychiatric symptom generation. QUIN has been shown to affect
glutamate neurotransmission via NMDAR agonism, which could be
a biological mechanism underlying suicidal behavior. The rapid
antidepressant and anti-suicidal effect of ketamine, which is an
NMDAR antagonist, could be due to its action on the same biolog-
ical pathway.
There are some difﬁculties in analyzing the role of the kynur-
enine pathway metabolites in suicidality, as well as in other
neuropsychiatric conditions, that are important to keep in mind.
Importantly, while blood samples are relatively easily obtained
from patients, the levels of kynurenine pathway metabolites in
these samples may not be reﬂective of the concentrations of the
same metabolites in the brain. On the contrary, it is possible that
the regulation and activity of the pathway are separate in the pe-
riphery versus the central compartment, as the BBB does not allow
for free penetrance of several metabolites into the CNS. Only a small
number of studies have looked into the correlation between the
levels of metabolites in the two compartments, and this area clearly
deserves future attention as the kynurenine metabolites are beingevaluated as potential candidates of peripheral biomarkers of
neuropsychiatric disease. CSF samples from patients are highly
valuable in this respect, although these samples still may not reﬂect
the actual conditions within each brain region of interest. In order
to fully understand the role of the kynurenine metabolites in
neuropsychiatric disease, biosamples from well-characterized pa-
tient groups should be paired with detailed animal studies, with
the possibility to directly study cause and effect of manipulating the
levels of metabolites in speciﬁc brain regions.
Another important factor to keep in mind is the handling of
biological samples, which may impact the detected levels of me-
tabolites. Once the samples are collected, the storage conditions
and the time elapsed between the sample collection and the start of
the experiment could differ between various laboratories. Post-
mortem samples are even more challenging because of the addi-
tional time spent from the time of death until the sample collection.
This could potentially inﬂuence the results due to the differences in
half-life and stability between different metabolites. For example,
while PIC and KYNA are stable metabolites that are excreted by the
liver and kidney, the half-life of QUIN in blood is only 20min, as this
metabolite is degraded by the down-stream enzyme QPRT
(Schwarcz et al., 2012). The half-life of individual metabolites is also
important to keep in mind for gene expression studies, where a
small or temporary increase in the expression of an enzyme pro-
ducing a stable metabolite can potentially have far greater biolog-
ical effects than a comparatively large increase in the expression of
an enzyme producing a metabolite with a short half-life.
Finally, the psychiatric diagnostic system and the nomenclature
regarding suicidality and suicidal behavior have inherent limita-
tions, as the classiﬁcations are man-made and may not exactly
represent biological disease entities. This should be kept in mind,
and as a consequence it may be wise to examine several aspects of
psychiatric behavior in a study, rather than focusing only on one
outcome measure. For example, in addition to comparing levels of
kynurenine metabolites in groups of patients with a diagnosis of
depression, the severity of symptoms can be investigated by rating
scales that analyze several aspects of depression. Similar clinical
assessment scales, investigating several aspects of suicidal
behavior, exist and allow a more complete examination of the
relation between speciﬁc symptoms of suicidality and the biolog-
ical changes.
A major goal of future studies will be to identify how, in suicidal
patients, enzymes in the kynurenine pathway become dysregu-
lated. Why do some metabolites accumulate more than others, and
what are the factors that convey vulnerability or resilience to
development of suicidal symptoms? It has been proposed that
genetic variations in the kynurenine pathway enzymes might be
associated with different expression rates or activity of the en-
zymes, which thus could affect the production of metabolites (Claes
et al., 2011). In addition, pro-inﬂammatory cytokines, which are
elevated in suicidal patients, are known to activate the initial step of
the kynurenine pathway, however, to what degree certain cyto-
kines may preferentially activate speciﬁc enzymes, especially
downstream in the pathway, is not currently known. As knowledge
regarding the regulation of the kynurenine pathway and the role of
its metabolites in suicidality increases, the enzymes of the pathway
may become attractive therapeutic targets for managing suicidal
behavior.
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